FDA-cleared AI tech provider Clever Culture Systems chooses sales agent

The company, which provides automated microbiological culture plate reading tech, has chosen its sole sales agent for pharmaceutical manufacturing for US, Canada and Singapore

PSC Biotech has been chosen as the sole Sales Agent for Clever Culture Systems’ APAS (registered trademark) Independence across the pharmaceutical manufacturing market in the US, Canada, and Singapore.

APAS Independence uses AI and machine learning to automate the imaging, analysis, and interpretation of microbiology culture plates.

This technology fits within the remit of RMM, or Rapid Microbial Methods, which are a major focus in the improvement of cleanroom operations in the future.

The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading. In pharmaceutical manufacturing environments, it reads environmental monitoring plates, helping microbiology laboratories reduce manual plate reading and improve consistency.

“We have successfully established APAS Independence with leading global pharmaceutical manufacturers. The PSC Biotech partnership provides a new, complementary channel to broaden our reach across the US pharmaceutical market, particularly into mid-tier and regional manufacturers," said Brent Barnes, CEO and Managing Director, Clever Culture Systems.

The PSC Biotech partnership provides a new, complementary channel to broaden our reach

The APAS Independence system also won the Best Environmental Monitoring Award in the Cleanroom Technology Awards this year.

Life science equipment sales expert PSC Biotech has been in operation for 30 years.

Throughout these years, PSC has experience in pharmaceutical consulting, validation, and compliance.

PSC Biotech will introduce APAS Independence to its established network of pharmaceutical manufacturers, providing customers with access to an established technology along with the local expertise to qualify and validate it within regulated GMP environments.

"Our relationships across the pharmaceutical industry give us a strong platform to introduce APAS® Independence to a much broader customer base," said PSC Biotech Corporation's CEO, John Clapham.

PSC Biotech now represents APAS Independence alongside the other advanced technologies it brings to the life sciences industry, including:

  • De Lama’s sterilisation and decontamination systems
  • Climet Instrument’s next-generation particle counters and microbial air samplers
  • Blue Ocean Robotics’ UVD Robot Pharma autonomous UV-C disinfection solution for cleanrooms

Together, these solutions support a modern contamination control strategy, from sterilisation and cleanroom disinfection to environmental monitoring.

“APAS Independence is a natural fit alongside the sterilisation and disinfection solutions we already offer," said Alfonso Fasano, Head of New Technologies, Partnerships & Innovation, PSC Biotech Corporation.

PSC to use APAS Independence in its own facility

As part of the partnership, PSC Biotech will install an APAS Independence instrument in BioTechnique, its sterile fill-finish contract manufacturing facility in York, Pennsylvania.

PSC Biotech Corporation has three unique active divisions within the parent company, each representing an area of expertise: PSC Biotech, PSC Software, and BioTechnique.

BioTechnique is the subsidiary that is a Contract Research, Development, and Manufacturing Organisation (CRDMO), specialising in cytotoxic and therapeutic sterile injectable fill-finish services.

The APA Independence system will be qualified and validated onsite for GMP use, establishing a US Center of Excellence where customers can see the technology at work in a live pharmaceutical manufacturing environment through demonstrations and evaluations.

"Combined with our validation capabilities and our Center of Excellence at BioTechnique, we can help customers adopt AI-enabled microbiology with confidence, from evaluation through to GMP use," Fasano added.

You may also like